Abstract
TMA is a rare complication of tacrolimus. Disruption of endothelial cells, platelet aggregation, and intravascular mechanical fragmentation of red cells are core mechanisms of injury; however, exact pathways of toxicity are not clear. The clinical presentation may vary but TMA is a potentially life-threatening condition usually demanding aggressive treatment. We present the case of TMA in a child after living-related liver transplantation (LRLTx) on tacrolimus-based immunosuppressive regiment successfully converted to sirolimus.
© 2011 John Wiley & Sons A/S.
MeSH terms
-
Anemia, Hemolytic / complications
-
Anemia, Hemolytic / therapy
-
Biopsy
-
Erythrocytes / drug effects
-
Female
-
Graft Survival
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Infant
-
Liver Failure / complications*
-
Liver Failure / therapy*
-
Liver Transplantation / methods*
-
Living Donors
-
Platelet Aggregation / drug effects
-
Sirolimus / therapeutic use*
-
Tacrolimus / adverse effects*
-
Tacrolimus / toxicity
-
Thrombotic Microangiopathies / chemically induced*
-
Thrombotic Microangiopathies / complications*
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Sirolimus
-
Tacrolimus